New Review Published in Immunotherapy Highlights the Potential for Clever-1 Inhibition with bexmarilimab to Become the Cornerstone of Next-Generation, Multi-Indication Cancer Immunotherapy

About this update from Faron Pharmaceuticals Oy

[{"type":"text","content":"Comprehensive review synthesizes clinical learnings from BEXMAB and MATINS trials, detailing the potential of bexmarilimab in overcoming immune resistance in cancer","length":164,"tagName":"p"},{"type":"text","content":"TURKU, FI / ACCESS Newswire / January 29, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announces the publication of a comprehensive review article in the prestigious peer-reviewed journal, Immunotherapy.","length":331,"tagName":"p"},{"type":"text","content":"The article, titled ‘ Clinical optimization of bexmarilimab as a myeloid checkpoint therapy,' provides a definitive scientific and translational analysis of Clever-1, a scavenger receptor expressed on immunosuppressive macrophages. It positions Clever-1 as a ‘foundational myeloid checkpoint,' essential for maintaining the immune-evasive environment that many aggressive cancers rely on to survive.","length":407,"tagName":"p"},{"type":"text","content":"Coming on the heels of the positive clinical data from the pivotal BEXMAB trial presented across five leading conferences in 2025, ending with American Society of Hematology (ASH) Annual Meeting in December, this review serves as a cornerstone bringing together years of research, clinical data, and future strategic positioning across multiple tumour types for Faron's lead candidate, bexmarilimab .","length":404,"tagName":"p"},{"type":"text","content":""This peer-reviewed publication is the culmination of our deep-rooted scientific understanding of the myeloid cell's role in cancer," said Dr. Maija Hollmén, senior author and Chief Scientific Officer of Faron Pharmaceuticals, and Adjunct Professor of Tumour Immunology, Group Leader, MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland. "By highlighting how bexmarilimab specifically reprograms Clever-1-positive macrophages from a pro-tumoral to a pro-inflammatory state, we are demonstrating that the immune system can be re-ignited. This review clarifies that targeting myeloid checkpoints is not just a secondary strategy, but a primary requirement for overcoming the immunosuppressive microenvironment that current therapies often fail to penetrate."","length":816,"tagName"...

More updates from Faron Pharmaceuticals Oy